Contemporary Clinical Trials

CeraVe Establishes Fund at Howard University to Address Lack of Diversity and Increase Representation of Skin of Color in Skincare Clinical Research

Retrieved on: 
Wednesday, November 16, 2022
Advertising, Technology, Pharmacy, Student, Research, Industry, National Institutes of Health, College, Skin, MVE, National, Schwarzman, Howard University, Leadership, Partnership, Howard University Hospital, University, Senior, Medicine, National Center for Research Resources, Department, Marketing, Clinical trial, Engineering, Historically black colleges and universities, Faculty, College of Medicine, S&E, L'Oréal, Population, Human services, School, African Americans, Multimedia, Certification, NIH, Color, Service, Science, Social media, NEW, Group, United States Department of Health and Human Services, Education, Thomas R. Pickering Foreign Affairs Fellowship, UIM, Employment, Contemporary Clinical Trials, Howard University College of Medicine, White, Cosmetics, Pharmaceutical industry, Hospital, Dermatology, Facebook, Black

NEW YORK, Nov. 16, 2022 /PRNewswire/ -- As a brand developed with dermatologists and backed by science, CeraVe is committed to providing safe and efficacious skincare products for all people and recognizes that there are representation gaps within the skincare industry. This includes representation at the clinical research level, both for participants of dermatological clinical trials and the investigators conducting them, of which there is a significant disparity for skin of color. To help close this existing racial inequity gap in dermatological research, CeraVe is establishing a fund at Howard University, one of the only historically Black universities with a Department of Dermatology, to help its faculty further their expertise and build the infrastructure needed to conduct clinical trials with a focus on skin of color.

Key Points: 
  • Diversity is not just lacking in those participating in clinical trials, but also in those conducting the trials.
  • The first stage of the partnership between CeraVe and Howard University, will help fund faculty education to obtain certification to conduct clinical trials.
  • By partnering with the Howard University Dermatology Department, CeraVe is helping the University become a leader in research and innovation of dermatological science for skin of color.
  • Both Howard University and CeraVe are committed to transform values into action to address the health inequities impacting people of color.

The Future of Clinical Trial Oversight: What Really Matters

Retrieved on: 
Wednesday, April 27, 2022
Clinical trial, NIH, Research, Science, National, Manasco, GlaxoSmithKline, Contemporary Clinical Trials, Method, CRO, Interview, Industry, Harvard Medical School, MANA, Time, Medical device, Pharmaceutical industry, Health, MD, Medicine

DENVER, April 27, 2022 /PRNewswire/ -- An evidence-based approach to clinical trial oversight is key to the future of clinical trial oversight, according to Deepak Bhatt, MD and Penelope Manasco, MD. Their newly published article, "Evaluating the evaluators," now available in Contemporary Clinical Trials, explains why. The authors hope the article will spur discussion within the industry and at NIH to address a critical need.

Key Points: 
  • DENVER, April 27, 2022 /PRNewswire/ -- An evidence-based approach to clinical trial oversight is key to the future of clinical trial oversight, according to Deepak Bhatt, MD and Penelope Manasco, MD.
  • Their newly published article, "Evaluating the evaluators," now available in Contemporary Clinical Trials , explains why.
  • "There is a great need for more research to identify and optimize methods of oversight of clinical trial monitoring.
  • "Clinical trial monitoring is a multibillion dollar industry.

L-Nutra Reports Initial Data Showing Improvements in Metabolic Risk Factors in Patients with Prostate Cancer

Retrieved on: 
Tuesday, April 19, 2022
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Fitness & Nutrition, FMT, Prostate, Ageing, CEO, European Prospective Investigation into Cancer and Nutrition, Microdeletion syndrome, Cardiovascular disease, Human, Weight gain, Risk, Waist, Sugar, Weight loss, Diagnosis, Life, Compliance, Obesity, Program, Patient, Growth, Survivor, Mortality, Flanders, Malnutrition, Overweight, Longevity, Breast cancer, Metabolism, Prostate cancer, Contemporary Clinical Trials, Man, PC, Fasting, PALS, HIV disease progression rates, Metabolic syndrome, Health, Overalls, Therapy, Cancer, Pharmaceutical industry, Medical imaging

Leveraging our insights into the complex interrelationships between metabolic determinants and cancer biology, L-Nutra is committed to developing the next generation of nutri-solutions for patients with cancer.

Key Points: 
  • Leveraging our insights into the complex interrelationships between metabolic determinants and cancer biology, L-Nutra is committed to developing the next generation of nutri-solutions for patients with cancer.
  • In addition, the treatment of prostate cancer with hormonal therapy often leads to metabolic syndrome.
  • L-Nutra plans to further evaluate the impact of FMT to support the metabolic health of cancer patients undergoing cancer therapy.
  • Postdiagnosis body mass index, weight change, and mortality from prostate cancer, cardiovascular disease, and all causes among survivors of nonmetastatic prostate cancer.

LivaNova Announces 250th Unipolar Depression Patient Implanted in RECOVER Clinical Study

Retrieved on: 
Monday, March 14, 2022
Research, Mental Health, Surgery, Hospitals, FDA, Clinical Trials, Biotechnology, General Health, Health, Science, Depression, Washington University in St. Louis, Trial of the century, TRD, Safety, Vagus nerve stimulation, Mortality, Effectiveness, Patient, PLC, Clinical trial, LIVN, Hope, LivaNova, FDA, Adjunct (grammar), Annual report, STAR, Data, CMS, Quality of life, RCT, Disability, Principal, Medicaid, Lists of diseases, Catherine Disher, News, Disease, Risk, VNS, Hospital, DTD, Contemporary Clinical Trials, Head, Population, Medicare, Randomized controlled trial, Grammatical mood, Cyclothymia, MDD, Pharmaceutical industry, Symmetry, VNS Therapy for Depression, LivaNova, VNS THERAPY FOR DEPRESSION, LIVANOVA

LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today announced the 250th unipolar depression patient has been implanted in the RECOVER clinical study , A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression.

Key Points: 
  • LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today announced the 250th unipolar depression patient has been implanted in the RECOVER clinical study , A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression.
  • The interim analyses will assess if predictive probability of success has been reached for the unipolar cohort of the study.
  • Implanting our 250th unipolar patient marks a major milestone in this groundbreaking depression study, said Dr. Charles R. Conway, Director of the Washington University Resistant Mood Disorders Center, who serves as Principal Investigator for RECOVER.
  • As interim analyses are conducted for the unipolar cohort, unipolar and bipolar depression patients will continue to be enrolled into the randomized controlled trial (RCT).